User profiles for Vamsidhar Velcheti

Vamsidhar Velcheti MD FACP FCCP

Yale University
Verified email at yale.edu
Cited by 16788

[HTML][HTML] Programmed death ligand-1 expression in non-small cell lung cancer

V Velcheti, KA Schalper, DE Carvajal… - Laboratory …, 2014 - Elsevier
Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1,
CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials…

Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology

K Bera, KA Schalper, DL Rimm, V Velcheti… - Nature reviews Clinical …, 2019 - nature.com
In the past decade, advances in precision oncology have resulted in an increased demand
for predictive assays that enable the selection and stratification of patients for treatment. The …

Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer

…, V Pelekanou, J Rehman, V Velcheti… - JAMA …, 2016 - jamanetwork.com
Importance Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell
death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable …

[PDF][PDF] CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer

…, J Donaghue, ES Wang, T Zhang, Z He, V Velcheti… - Cancer cell, 2020 - cell.com
Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription.
However, little is known about its impact on genomic instability and cancer immunity. …

[HTML][HTML] Sotorasib for Lung Cancers with KRAS p.G12C Mutation

…, G Friberg, V Velcheti… - … England Journal of …, 2021 - Mass Medical Soc
Background Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …

Predicting cancer outcomes with radiomics and artificial intelligence in radiology

K Bera, N Braman, A Gupta, V Velcheti… - Nature reviews Clinical …, 2022 - nature.com
The successful use of artificial intelligence (AI) for diagnostic purposes has prompted the
application of AI-based cancer imaging analysis to address other, more complex, clinical needs…

[HTML][HTML] Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

…, F De Braud, E Garralda, V Velcheti… - … England Journal of …, 2020 - Mass Medical Soc
Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs).
In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

[HTML][HTML] The current state of the art and future trends in RAS-targeted cancer therapies

SR Punekar, V Velcheti, BG Neel… - Nature reviews Clinical …, 2022 - nature.com
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable …

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

KA Schalper, V Velcheti, D Carvajal, H Wimberly… - Clinical cancer …, 2014 - AACR
Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option
for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and …

Radiomics and radiogenomics in lung cancer: a review for the clinician

…, M McLane, N Beig, S Ghose, P Prasanna, V Velcheti… - Lung cancer, 2018 - Elsevier
Lung cancer is responsible for a large proportion of cancer-related deaths across the globe,
with delayed detection being perhaps the most significant factor for its high mortality rate. …